STRR vs. DRIO, MDAI, PTHL, NMTC, TMDIF, FEMY, PYPD, OSRH, QTI, and RVP
Should you be buying Star Equity stock or one of its competitors? The main competitors of Star Equity include DarioHealth (DRIO), Spectral AI (MDAI), Pheton Holdings Ltd Class A Ordinary Shares (PTHL), NeuroOne Medical Technologies (NMTC), Titan Medical (TMDIF), Femasys (FEMY), PolyPid (PYPD), OSR (OSRH), QT Imaging (QTI), and Retractable Technologies (RVP). These companies are all part of the "medical equipment" industry.
Star Equity vs.
Star Equity (NASDAQ:STRR) and DarioHealth (NASDAQ:DRIO) are both small-cap multi-sector conglomerates companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, dividends, profitability, institutional ownership, community ranking, risk and valuation.
Star Equity currently has a consensus price target of $5.00, indicating a potential upside of 124.72%. DarioHealth has a consensus price target of $2.00, indicating a potential upside of 189.81%. Given DarioHealth's higher probable upside, analysts plainly believe DarioHealth is more favorable than Star Equity.
Star Equity has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500. Comparatively, DarioHealth has a beta of 1.55, meaning that its stock price is 55% more volatile than the S&P 500.
Star Equity has a net margin of -12.41% compared to DarioHealth's net margin of -205.62%. Star Equity's return on equity of -8.72% beat DarioHealth's return on equity.
In the previous week, Star Equity had 4 more articles in the media than DarioHealth. MarketBeat recorded 10 mentions for Star Equity and 6 mentions for DarioHealth. Star Equity's average media sentiment score of -0.16 beat DarioHealth's score of -0.30 indicating that Star Equity is being referred to more favorably in the media.
Star Equity has higher revenue and earnings than DarioHealth. DarioHealth is trading at a lower price-to-earnings ratio than Star Equity, indicating that it is currently the more affordable of the two stocks.
3.8% of Star Equity shares are owned by institutional investors. Comparatively, 33.4% of DarioHealth shares are owned by institutional investors. 33.5% of Star Equity shares are owned by company insiders. Comparatively, 10.9% of DarioHealth shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
DarioHealth received 236 more outperform votes than Star Equity when rated by MarketBeat users. However, 100.00% of users gave Star Equity an outperform vote while only 67.04% of users gave DarioHealth an outperform vote.
Summary
Star Equity beats DarioHealth on 10 of the 18 factors compared between the two stocks.
Get Star Equity News Delivered to You Automatically
Sign up to receive the latest news and ratings for STRR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Star Equity Competitors List
Related Companies and Tools
This page (NASDAQ:STRR) was last updated on 5/22/2025 by MarketBeat.com Staff
